Effects of Meditation on Mechanism of Coronary Heart Disease
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To study the effects of Transcendental Meditation on Coronary Heart Disease
| Condition | Intervention | Phase |
|---|---|---|
|
Coronary Heart Disease |
Procedure: Meditation |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Primary Purpose: Treatment |
| Official Title: | Effects of Meditation on Mechanism of Coronary Heart Disease |
| Estimated Enrollment: | 145 |
| Study Start Date: | September 1999 |
| Estimated Study Completion Date: | August 2002 |
Recent advances in our understanding of the pathophysiology of acute cardiac events - specifically, identification of the roles that arterial vasomotor dysfunction and autonomic nervous system imbalances play in the pathophysiologic cascade during such acute events - provides a platform for new mechanistic investigation of the interplay of psychosomatic stress and CHD (coronary heart disease). Preliminary evidence further suggests that Complementary and Alternative Medicine (CAM) practices, such as the Transcendental Meditation (TM) technique, can not only reduce stress but also reduce acute cardiac events in patients with CHD. Based on these and related data, we propose a randomized, blinded, controlled study of the effects of one CAM practice, the TM technique, compared to a control group, on the primary outcomes of (1) arterial vasomotor dysfunction (brachial artery reactivity); (2) autonomic nervous system imbalances (heart rate variability); (3) transient myocardial ischemia (ST-segment depression); and (4) the secondary outcomes of psychological stress and quality of life (anger, hostility, anxiety, depression, perceived health, disease-specific symptoms, and life stress/social resources).
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Able to attend training sessions and meetings
- Local residence
Exclusion Criteria:
- Comorbid disease precluding survival in group
- MI, unstable angina, CABG or PTCA within last three months.
- Cognitive/psychological/substance abuse impairment
- Atrial fibrillation, predominant pacemaker rhythm or significant conduction system disease
- Significant valvular heart disease
- Class III or IV heart failure
- Renal failure
- Participating in a formal stress management program
- Participation in another trial
Contacts and Locations| United States, California | |
| Preventive and Rehabilitative Cardiac Center | |
| Los Angeles, California, United States | |
| Principal Investigator: | C. Noel Bairey Merz, M.D. | Preventive and Rehabilitative Cardiac Center |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00010738 History of Changes |
| Obsolete Identifiers: | NCT00009399 |
| Other Study ID Numbers: | R01 AT000226-01M, R01 AT000226-01 |
| Study First Received: | February 2, 2001 |
| Last Updated: | August 17, 2006 |
| Health Authority: | United States: Federal Government |
Additional relevant MeSH terms:
|
Coronary Artery Disease Myocardial Ischemia Coronary Disease Heart Diseases |
Cardiovascular Diseases Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases |
ClinicalTrials.gov processed this record on May 22, 2013